These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B. JAMA; 2014 Dec 03; 312(21):2223-33. PubMed ID: 25402495 [Abstract] [Full Text] [Related]
23. Sodium zirconium cyclosilicate in hyperkalemia. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B. N Engl J Med; 2015 Jan 15; 372(3):222-31. PubMed ID: 25415807 [Abstract] [Full Text] [Related]
27. Novel approaches to management of hyperkalaemia in kidney transplantation. Rizk J, Quan D, Gabardi S, Rizk Y, Kalantar-Zadeh K. Curr Opin Nephrol Hypertens; 2021 Jan 15; 30(1):27-37. PubMed ID: 33027094 [Abstract] [Full Text] [Related]
28. Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease. Li L, Budden J, Quinn CM, Bushinsky D. J Cardiovasc Pharmacol Ther; 2024 Jan 15; 29():10742484241227580. PubMed ID: 38311939 [Abstract] [Full Text] [Related]
29. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent. Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K, Dhawan P, Nobakht N, Kamgar M, Goshtaseb R, Sarmosyan K, Gnarini M, Wassef O, Lerma E. Expert Rev Clin Pharmacol; 2021 Sep 15; 14(9):1055-1064. PubMed ID: 34227913 [Abstract] [Full Text] [Related]
35. Safety and efficacy of sodium zirconium cyclosilicate for the management of acute and chronic hyperkalemia in children with chronic kidney disease 4-5 and on dialysis. Khandelwal P, Shah S, McAlister L, Cleghorn S, King L, Shroff R. Pediatr Nephrol; 2024 Apr 07; 39(4):1213-1219. PubMed ID: 37857905 [Abstract] [Full Text] [Related]
37. Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study. Wheeler DC, Søndergaard H, Gwynn C, Hedman K, Hedberg J, Allum A, Chung HL, Någård M, Stjernlöf G, Wittbrodt E, Kim J, Morris J. BMJ Open; 2024 Feb 21; 14(2):e074954. PubMed ID: 38387989 [Abstract] [Full Text] [Related]